|
|
在研机构- |
|
在研适应症- |
|
最高研发阶段无进展 |
首次获批国家/地区- |
首次获批日期- |
A Phase I, double-blind, placebo-controlled, randomised, crossover study to assess the anti-inflammatory effects of orally inhaled PB01 following an inhaled lipopolysaccharide (LPS) challenge in healthy male volunteers.
Randomised, double-blind, placebo-controlled Phase I study to evaluate the safety, tolerability and pharmacokinetics of single and multiple doses of orally inhaled PB01 administered to healthy subjects.
100 项与 Paranta Biosciences Ltd. 相关的临床结果
0 项与 Paranta Biosciences Ltd. 相关的专利(医药)
100 项与 Paranta Biosciences Ltd. 相关的药物交易
100 项与 Paranta Biosciences Ltd. 相关的转化医学